Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News ViaDerma Inc VDRM

Healthcare

ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Company’s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating... see more

Add To Watchlist

Recent & Breaking News (OTCPK:VDRM)

Developments in the Erectile Dysfunction Markets

PR Newswire August 28, 2017

ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan

Marketwired August 18, 2017

ViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product

Marketwired July 27, 2017

ViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results

MarketWire Canada July 10, 2017

ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for Men

MarketWire Canada June 27, 2017

ViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow

MarketWire Canada June 15, 2017

ViaDerma, Inc. Commences First Manufacturing Run and will Meet the 2nd Quarter Product Distribution Milestone

MarketWire Canada June 12, 2017

ViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies

Marketwired May 15, 2017

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

MarketWire Canada May 3, 2017

ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

MarketWire Canada April 19, 2017

ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

MarketWire Canada April 5, 2017

ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

MarketWire Canada March 20, 2017

ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

MarketWire Canada March 8, 2017

ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

MarketWire Canada February 15, 2017

Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes Science and Technology, a leading US Publication for Diabetes

MarketWire Canada February 8, 2017

ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017, also Onychomycosis Clinical Studies Show Significant Results

MarketWire Canada February 3, 2017

ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling Viabecline Through Established Online Distribution Networks in 2017

MarketWire Canada January 11, 2017

ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions

MarketWire Canada November 30, 2016

ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis

MarketWire Canada November 14, 2016

Timing is Crucial, Upside Analysis - Complementary Research on Viaderma, Imageware Systems, Secom and Brambles

Accesswire March 10, 2016